Here Are Biotech’s Big Pipeline Disappointments in 2018

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=14rQnFtsRLY

Biotech is notorious for clinical- trial pipeline failures and 2018 had its fair share of clinical trial setbacks. • In this clip from The Motley Fool’s Industry Focus: Healthcare, analyst Shannon Jones and Todd Campbell discuss a few of the highest-profile clinical trial setbacks, including disappointments at Celgene (NASDAQ: CELG), Incyte (NASDAQ: INCY), and Geron Corp. (NASDAQ: GERN). • ------------------------------------------------------------------------ • Subscribe to The Motley Fool's YouTube Channel: • / themotleyfool • Or, follow our Google+ page: • https://plus.google.com/+MotleyFool/p... • Inside The Motley Fool: Check out our Culture Blog! • http://culture.fool.com • Join our Facebook community: • / themotleyfool • Follow The Motley Fool on Twitter: • / themotleyfool

#############################

New on site